SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders debating whether guidance, subscriber engagement and ad growth can offset concerns about slowing growth and the content slate. Sentiment leans bearish amid the stocks decline and traders claims of repeated post-earnings selloffs, though some see low expectations as room for a rebound.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A sharp rebound and heavy buying have fueled attention as traders anticipate the 80th-event trigger and final-analysis results for SELLASs Phase 3 REGAL trial of GPS. Some also read the CEOs anniversary remarks and planned ASH presence as possible buyout signals, but others stress there is no confirmed deal or trial result and that the price move may be trading activity.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly earnings and forward guidance are the dominant focus, particularly whether AI and data-center revenue can justify heavy capital spending. Traders are split between expecting a profitable report and rally and worrying about debt, spending, valuation, and an upcoming share unlock.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets reported Willow quantum-computing advanceusing magic state cultivation to cut errors roughly 40-foldhas sparked interest, though traders question whether it will matter to the stock near term as the share price remains weak. Conversation also centers on the upcoming earnings report and whether the recent pullback is a buying opportunity or reflects broader tech and AI-spending concerns.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs rise is being linked by traders both to strength across biotech and to the reported Silence Therapeutics acquisition, which some see as a sign of pharma interest in siRNA therapies relevant to Sareptas pipeline. Others view the move as a sector-driven bounce or short covering, and say upcoming DM1 and FSHD datanot a confirmed Sarepta-specific announcementwill be key.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas potential Monee fintech listing and launch of its Sea Cloud AI venture are fueling debate as shares sell off: some traders see a possible Monee separation and cloud investment as sources of uncertainty, while others argue the moves could unlock value and expand growth. The decline has intensified bearish technical commentary and speculation about insider selling, alongside bullish claims that the reaction is an overreaction.

Alphabet Inc - Ordinary Shares - Class C

Alphabets upcoming earnings are the main focus, with traders watching Google Cloud and Gemini for signs of growth. The discussion is divided between optimism about AI and cloud momentum and concern that heavy AI spending, alongside recent share-price weakness, could weigh on returns.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is drawing attention as traders position around the detailed Phase 3 results for its personalized melanoma cancer vaccine with Merck at ESMO, following a positive topline readout. Bulls see the data as validation of its oncology platform, while skeptics warn that the sharp rally may have priced in strong results and could reverse on a sell-the-news reaction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM shares are falling despite a third-quarter earnings and revenue beat and a new buyback authorization, as investors focus on a narrowed full-year profit outlook with its midpoint unchanged rather than an upgrade. Traders are split between viewing the selloff as overdone given stronger cash-flow guidance and capital returns, and seeing the outlook and softer vehicle sales as reasons for caution.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs steep selloff is drawing attention amid broader funding and return concerns for AI-focused neoclouds, with traders also questioning the companys execution, dilution and delayed Horizon capacity. Co-CEO Daniel Roberts comments that data-center construction has been cash-funded and customer prepayments help finance GPUs are cited by bulls, but have not eased the bearish debate or frustration that IREN is lagging peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Phreesia (PHR) Q2 2027 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Why Phreesia Stock Got Knocked Down Today

Key PointsThis added to lingering negative sentiment following the company's latest earnings release...

Why Phreesia Stock Tumbled Today

Key PointsAlthough its net income rose sharply, analysts expected better...

These Analysts Revise Their Forecasts On Phreesia After Q2 Results

Phreesia's Q2 EPS missed estimates, while sales beat. FY27 guidance held; shares fell 5.6%. Analysts kept bullish targets, Wells Fargo raised to $10.read more...

Phreesia (PHR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Phreesia (PHR) give insight into how the company performed in the quarter ended July 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Transcript: Phreesia Q2 2027 Earnings Conference Call

Phreesia (NYSE:PHR) reported second-quarter financial results on Wednesday. The transcript from the company's second-quarter earnings call has been provided below.
This content is powered by Benzinga APIs. Forread more...

Phreesia (PHR) Q2 Earnings and Revenues Lag Estimates

Phreesia (PHR) delivered earnings and revenue surprises of -72.73% and -0.13%, respectively, for the quarter ended July 2026. Do the numbers hold clues to what lies ahead for the stock?

Phreesia Announces Second Quarter Fiscal 2027 Results

Phreesia, Inc. (NYSE: PHR) (Phreesia or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2026. Phreesia delivered a solid fiscal second quarter, with revenue growth and profitability expansion in line with our expectations. We generated positive...

Veeva Systems (VEEV) Q2 Earnings and Revenues Beat Estimates

Veeva (VEEV) delivered earnings and revenue surprises of +5.86% and +2.64%, respectively, for the quarter ended July 2026. Do the numbers hold clues to what lies ahead for the stock?

NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates

NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of -100.00% and -54.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Phreesia, Inc. engages in the provision of patient check-in solutions for medical practices. The firm offers appointments, clinical support, integration, registration, patient activation, analytics and reports, revenue cycle, patient surveys, and privacy and security products. Its solutions include health systems, multi-specialty, and federally qualified health centers (FQHCs). The company was founded by Chaim Indig and Evan Roberts in January 2005 and is headquartered in Wilmington, DE.

Phreesia Inc

Why PEPG, SGMO, PHR Are Among Top Premarket Losers Today

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>PEPG fell after its Phase 2 Freedom 2 study showed no meaningful improvements in walking speed or hand strength at the starting dose of 5 mg/kg.</li><li>SGMO slipped after reporting a Q4 loss per share of $0.11 versus the expected loss of $0.05, even as revenue rose to $14.23 million from $7.55 million a year earlier.</li><li>PHR declined after cutting its FY27 revenue outlook to $510 million-$520 million from $545 million-$559 million, below analyst expectations of $552.1 million.</li></ul>Shares of PepGen (PEPG), Sangamo Therapeutics (SGMO), and Phreesia (PHR) were among the top premarket losers on Tuesday as investors reacted to muted functional trial results, a wider-than-expected loss, and a revenue outlook cut, prompting analyst downgrades.In early premarket trading on Tuesday, PEPG plunged 45%, SGMO fell 19%, and PHR slumped 27%.<h2 class="st-heading-2">PepGen Trial Shows No Functional Gains At Low Dose</h2>PepGen reported results from the lowest-dose cohort in its Phase 2 Freedom 2 study of PGN-EDODM1 in patients with myotonic dystrophy type 1, with investors focusing on the lack of functional improvement at the starting dose.The company said the therapy was generally well tolerated, with all adverse events mild or moderate and no serious adverse events reported. However, the company also said patients showed “no meaningful improvements” in walking speed or hand strength at the starting 5 mg/kg dose of PGN-EDODM1.PepGen said patients receiving the treatment showed an average 7.3% improvement on a disease-related molecular metric, compared with 6.8% in placebo patients, rising to 22.9% after excluding one outlier. The company expects results from the higher 10 mg/kg cohort in the second half of 2026, with cash expected to support operations into the second half of 2027.<h2 class="st-heading-2">Sangamo Loss Widens As Funding Outlook Weighs</h2>Sangamo Therapeutics reported a fourth-quarter (Q4) loss per share of $0.11, wider than analyst expectations for a loss of $0.05, even as revenue rose to $14.23 million from $7.55 million a year earlier.The company highlighted progress in its Fabry disease gene therapy program, saying it is “well advanced in the rolling submission of the BLA to the FDA under the Accelerated Approval pathway” following positive topline results from the registrational STAAR study.However, sentiment appeared pressured after the company said its 2026 expense outlook is “subject to our ability to secure adequate additional funding for our current operating plan.” Sangamo expects non-GAAP operating expenses of $110 million to $120 million in 2026.<h2 class="st-heading-2">Phreesia Guidance Cut Triggers Broker Downgrades</h2>Phreesia reported Q4 revenue of $127.1 million, slightly above analyst expectations of $126.6 million, while adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rose to $29.4 million from $16.4 million a year earlier.Shares fell after the company lowered its fiscal 2027 revenue outlook to $510 million to $520 million, down from $545 million to $559 million, and below analyst expectations of $552.1 million. The company said, “Network solutions clients are committing lower spend levels for the second half of fiscal 2027 than we had anticipated last December.”Following the guidance cut, Baird downgraded the stock to ‘Neutral’ from ‘Outperform’ and reduced its price target to $10 from $25, saying “the magnitude of the follow-on impact exceeded expectations.” Truist Securities also downgraded the stock to ‘Hold’ from ‘Buy’ and lowered its price target to $11 from $24, citing “the meaningful reduction to the revenue outlook.”<h2 class="st-heading-2">How Do Retail Traders Feel About PEPG, SGMO And PHR?</h2>On Stocktwits, retail sentiment for PEPG, SGMO and PHR was ‘extremely bullish’ amid ‘extremely high’ message volume.Over the past year, PEPG has risen 186%, while SGMO has fallen 63% and PHR has declined 56%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/unh-stock-below-buffett-entry-price-first-revenue-decline-30-years-ai/cZEPohoRINz">UNH Stock Slides Back Below Warren Buffett’s Entry Price As Annual Revenue Faces First Decline In 30 Years — AI May Be Long-Term Fix</a>

However, retail sentiment on Stocktwits across all three firms was ‘extremely bullish’ amid ‘extremely high’ message volumes.  In early premarket trading on Tuesday, PEPG plunged 45%, SGMO fell 19%, and PHR slumped 27%

However, retail sentiment on Stocktwits across all three firms was ‘extremely bullish’ amid ‘extremely high’ message volumes.

PepGen Inc

Sangamo Therapeutics Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$12.02
Prev Close	$11.28
Open	$11.38
Dividend Yield	0.00%
50-Day Moving Average	$10.98
Beta	1.14
Avg. Volume	756,591.67
PE Ratio	66.79

52-Week High	$24.07
52-Week Low	$7.77
Market Capitalization	$700.16M
EPS (Annual)	$0.0375
Price to Book	1.88
Revenue Per Employee	$268,636.67

Feed

News

Sentiment

Earnings

Fundamentals

Info

PHR Fundamentals